433 related articles for article (PubMed ID: 22014572)
1. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.
Cai C; He HH; Chen S; Coleman I; Wang H; Fang Z; Chen S; Nelson PS; Liu XS; Brown M; Balk SP
Cancer Cell; 2011 Oct; 20(4):457-71. PubMed ID: 22014572
[TBL] [Abstract][Full Text] [Related]
2. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
[TBL] [Abstract][Full Text] [Related]
3. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.
Agoulnik IU; Bingman WE; Nakka M; Li W; Wang Q; Liu XS; Brown M; Weigel NL
Mol Endocrinol; 2008 Nov; 22(11):2420-32. PubMed ID: 18787043
[TBL] [Abstract][Full Text] [Related]
4. Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity.
Roggero CM; Esser V; Duan L; Rice AM; Ma S; Raj GV; Rosen MK; Liu ZP; Rizo J
PLoS One; 2022; 17(1):e0258876. PubMed ID: 34986150
[TBL] [Abstract][Full Text] [Related]
5. JMJD2A promotes the development of castration-resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS-STING pathway.
Cai X; Yu X; Tang T; Xu Y; Wu T
Mol Carcinog; 2024 May; ():. PubMed ID: 38818897
[TBL] [Abstract][Full Text] [Related]
6. Novel Insights on the Role of Epigenetics in Androgen Receptor's Expression in Prostate Cancer.
Camilo V; Pacheco MB; Moreira-Silva F; Outeiro-Pinho G; Gaspar VM; Mano JF; Marques CJ; Henrique R; Jerónimo C
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892208
[TBL] [Abstract][Full Text] [Related]
7. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C
Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846
[TBL] [Abstract][Full Text] [Related]
8. IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.
DiNatale A; Worrede A; Iqbal W; Marchioli M; Toth A; Sjöström M; Zhu X; Corey E; Feng FY; Zhou W; Fatatis A
Cancer Res Commun; 2022 Dec; 2(12):1545-1557. PubMed ID: 36561929
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.
Ito S; Liu X; Ishikawa Y; Conti DD; Otomo N; Kote-Jarai Z; Suetsugu H; Eeles RA; Koike Y; Hikino K; Yoshino S; Tomizuka K; Horikoshi M; Ito K; Uchio Y; Momozawa Y; Kubo M; ; Kamatani Y; Matsuda K; Haiman CA; Ikegawa S; Nakagawa H; Terao C
Nat Commun; 2023 Aug; 14(1):4863. PubMed ID: 37612283
[TBL] [Abstract][Full Text] [Related]
10. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.
Cai C; He HH; Gao S; Chen S; Yu Z; Gao Y; Chen S; Chen MW; Zhang J; Ahmed M; Wang Y; Metzger E; Schüle R; Liu XS; Brown M; Balk SP
Cell Rep; 2014 Dec; 9(5):1618-1627. PubMed ID: 25482560
[TBL] [Abstract][Full Text] [Related]
11. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
12. Integrative clinical genomics of advanced prostate cancer.
Robinson D; Van Allen EM; Wu YM; Schultz N; Lonigro RJ; Mosquera JM; Montgomery B; Taplin ME; Pritchard CC; Attard G; Beltran H; Abida W; Bradley RK; Vinson J; Cao X; Vats P; Kunju LP; Hussain M; Feng FY; Tomlins SA; Cooney KA; Smith DC; Brennan C; Siddiqui J; Mehra R; Chen Y; Rathkopf DE; Morris MJ; Solomon SB; Durack JC; Reuter VE; Gopalan A; Gao J; Loda M; Lis RT; Bowden M; Balk SP; Gaviola G; Sougnez C; Gupta M; Yu EY; Mostaghel EA; Cheng HH; Mulcahy H; True LD; Plymate SR; Dvinge H; Ferraldeschi R; Flohr P; Miranda S; Zafeiriou Z; Tunariu N; Mateo J; Perez-Lopez R; Demichelis F; Robinson BD; Schiffman M; Nanus DM; Tagawa ST; Sigaras A; Eng KW; Elemento O; Sboner A; Heath EI; Scher HI; Pienta KJ; Kantoff P; de Bono JS; Rubin MA; Nelson PS; Garraway LA; Sawyers CL; Chinnaiyan AM
Cell; 2015 May; 161(5):1215-1228. PubMed ID: 26000489
[TBL] [Abstract][Full Text] [Related]
13. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
[TBL] [Abstract][Full Text] [Related]
14. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Kashyap V; Ahmad S; Nilsson EM; Helczynski L; Kenna S; Persson JL; Gudas LJ; Mongan NP
Mol Oncol; 2013 Jun; 7(3):555-66. PubMed ID: 23384557
[TBL] [Abstract][Full Text] [Related]
15. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
16. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
17. The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
19. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; van der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH
Cancer Res; 2017 Oct; 77(20):5479-5490. PubMed ID: 28916652
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
